New treatment yields complete regression of a human cancer in mice

A simple modification in an anti-cancer treatment currently in clinical trials substantially improves the drug’s effectiveness and reduces side effects in experiments with laboratory mice, researchers are reporting in an article scheduled for the May 16 edition of ACS’ Bioconjugate Chemistry. Enzon Pharmaceuticals’ David Filpula and colleagues at the National Cancer Institute worked on SS1P, a so-called immunotoxin that targets and destroys cells producing the surface protein mesothelin.

If you want to include this story in your blog, copy and paste this formatted text:

<p><a href="http://www.physorg.com/news96566183.html">New treatment yields complete regression of a human cancer in mice</a></p> <p>A simple modification in an anti-cancer treatment currently in clinical trials substantially improves the drug’s effectiveness and reduces side effects in experiments with laboratory mice, researchers are reporting in an article scheduled for the May 16 edition of ACS’ <i>Bioconjugate Chemistry</i>. Enzon Pharmaceuticals’ David Filpula and colleagues at the National Cancer Institute worked on SS1P, a so-called immunotoxin that targets and destroys cells producing the surface protein mesothelin.</p>